Arbutus Biopharma Corp - FORM 10-K - EX-21.1 - EXHIBIT 21.1 - March 16, 2018

Attached files

file filename
EX-32.2 - EXHIBIT 32.2 - Arbutus Biopharma Corpexhibit322_soxcertcfo.htm
EX-32.1 - EXHIBIT 32.1 - Arbutus Biopharma Corpexhibit321_soxcertceo.htm
EX-31.2 - EXHIBIT 31.2 - Arbutus Biopharma Corpexhibit312_10-kcertcfo.htm
EX-31.1 - EXHIBIT 31.1 - Arbutus Biopharma Corpexhibit311_10-kcertceo.htm
EX-23.1 - EXHIBIT 23.1 - Arbutus Biopharma Corpexhibit231_kpmg.htm
EX-10.77 - EXHIBIT 10.77 - Arbutus Biopharma Corpexhibit1077_koertvandenend.htm
EX-10.76 - EXHIBIT 10.76 - Arbutus Biopharma Corpexhibit1076_koertvandenend.htm
EX-10.75 - EXHIBIT 10.75 - Arbutus Biopharma Corpexhibit1075_brucecousinscf.htm
EX-3.1 - EXHIBIT 3.1 - Arbutus Biopharma Corpexhibit31_articlesandartic.htm
10-K - 10-K - Arbutus Biopharma Corparbutus10k2017.htm
Exhibit 21.1
 
Arbutus Biopharma Corporation
 
List of Subsidiaries
 
Name
Date on which the entity
became Arbutus’ wholly
owned sub
Jurisdiction
Protiva Biotherapeutics Inc.
May 30, 2008
British Columbia, Canada
Arbutus Biopharma Inc.
Mar. 4, 2015
Delaware, United States of America


Stock widget

Investing forum

Arbutus Biopharma Corp Reports